What happened
Bukwang Pharmaceutical IND filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$38.5M (+33.8% year on year), operating profit of US$952K (−30% year on year) and net income of US$937K (−78.3% year on year).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$38.5M |
|---|---|
| Revenue vs a year earlier | +33.8% |
| Operating profit | US$952K |
| Net income | US$937K |
| Period | Q2 2026 (consolidated) |
| Filed | 2026-07-21, Operating results (consolidated) (preliminary) (fair disclosure) |
| Source | DART rcept 20260721800615 → open original filing |
Source: DART. Information only, not investment advice.